The updated Phase 1a data and investor call could drive near-term volatility. Traders should watch for the abstract details at KCRS on July 24 and management commentary on July 27. The ongoing Phase 1b and planned Phase 3 registrational study (2028) keep the catalyst path intact but distant.
Price Chart
Executive Summary
Kura Oncology announced an oral presentation of updated Phase 1a data from its FIT-001 trial of darlifarnib plus cabozantinib in advanced ccRCC at the 2026 Kidney Cancer Research Summit. The data show long-term follow-up in heavily pretreated cabozantinib-naïve patients, supporting the combination's potential. A virtual investor call is scheduled for July 27, 2026, following the presentation.
Key Facts
- Oral presentation at 2026 KCRS on July 24, 2026, featuring updated Phase 1a data from FIT-001 trial of darlifarnib + cabozantinib in advanced ccRCC.
- Data are long-term follow-up in heavily pretreated, cabozantinib-naïve patients with refractory RCC.
- Global randomized Phase 1b dose-optimization portion of FIT-001 (darlifarnib + cabozantinib vs. cabozantinib alone) is ongoing.
- Registrational Phase 3 study planned for 2028.
- Virtual investor call on July 27, 2026 at 8:00 a.m. ET.
- Darlifarnib is a next-generation FTI designed to inhibit farnesylation of RHEB and suppress mTORC1 signaling.
Financial Impact
No financial data provided; no changes to revenue, guidance, or cash runway disclosed.
Risk Factors
- Updated Phase 1a data may not show meaningful differentiation vs. prior results.
- Phase 1b and planned Phase 3 are years away; no near-term registration catalyst.
- Competitive landscape for ccRCC combinations remains intense.
- Darlifarnib's broader combination strategy (PDAC with daraxonrasib) is early-stage and unvalidated.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3326716 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | 8-K | $12.09 $11.37 | ▼ −6.00% | ▼ −5.66% | $10.65 (−11.91%) |
Sep 8, 2026 24d ago | 8-K | $12.52 $11.30 | ▼ −9.74% | ▼ −8.63% | $10.65 (−14.94%) |
Aug 24, 2026 5w ago | Insider Cluster | $12.40 $12.65 | ▲ +2.02% | ▲ +1.55% | $10.65 (−14.11%) |
Aug 21, 2026 6w ago | Insider Cluster | $11.89 $12.66 | ▲ +6.48% | ▲ +6.00% | $10.65 (−10.43%) |
Aug 17, 2026 6w ago | Insider Buy | $12.33 $13.59 | ▲ +10.22% | ▲ +10.42% | $10.65 (−13.63%) |
Aug 12, 2026 7w ago | Press Release | $10.09 $11.71 | ▲ +16.06% | ▲ +18.02% | $10.65 (+5.55%) |
Aug 5, 2026 8w ago | Press Release | $9.20 $9.94 | ▲ +8.04% | ▲ +7.69% | $10.65 (+15.76%) |
Jul 29, 2026 9w ago | 8-K | $9.31 $9.28 | ▼ −0.32% | ▼ −3.94% | $10.65 (+14.39%) |
Jul 14, 2026 11w ago | Press Release | $11.24 $10.68 | ▼ −4.98% | ▼ −3.69% | $10.65 (−5.25%) |
Jun 3, 2026 17w ago | Press Release | $8.66 $8.68 | ▲ +0.29% | ▲ +4.11% | $10.65 (+23.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access